Großbritannien

Aquis Stock Exchange: TECHNICAL MARKET UPDATE - SATIVA WELLNESS GROUP INC.

Thursday, October 1, 2020 - 5:04pm

Aquis Stock Exchange: TECHNICAL MARKET UPDATE - SATIVA WELLNESS GROUP INC.

Key Points: 
  • Aquis Stock Exchange: TECHNICAL MARKET UPDATE - SATIVA WELLNESS GROUP INC.
    TECHNICAL MARKET UPDATE - SATIVA WELLNESS GROUP INC.
    AQSE is aware that, due to an Exchange technical issue, trading on the AQSE Growth Market in the securities of Sativa Wellness Group Inc. (SWEL, ISIN: CA80403E1043) scheduled for 08.00, 01/10/2020 has been impacted on certain systems.
  • The issue is of a technical nature only.
  • Sativa Wellness Group Inc's admission to the AQSE Growth Market and its standing has not been impacted.
  • A market update will follow once the system issues have been resolved.

Renewi plc: Block listing six monthly return

Thursday, October 1, 2020 - 4:10pm

Balance of unallotted securities under scheme(s) from previous return:

Key Points: 

Balance of unallotted securities under scheme(s) from previous return:
Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

Travis Perkins: Director/PDMR Shareholding

Thursday, October 1, 2020 - 3:10pm

Travis Perkins plc ("the Company") has been notified that the PDMRs listed below acquired ordinary shares of 10 pence each ('Shares') in the Company on 1 October 2020 at a share price of £11.034849 in accordance with the Company's non-executive director fee structure.

Key Points: 

Travis Perkins plc ("the Company") has been notified that the PDMRs listed below acquired ordinary shares of 10 pence each ('Shares') in the Company on 1 October 2020 at a share price of £11.034849 in accordance with the Company's non-executive director fee structure.

LogicBio announces pricing of public offering

Thursday, October 1, 2020 - 3:10pm

LONDON, 01 October 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company LogicBio Therapeutics, Inc. (NASDAQ: LOGC) ("LogicBio"), has announced the pricing of its underwritten public offering in the United States of 7,000,000 shares of common stock, at a public offering price of $6.00 per share, for total gross proceeds of approximately $42.0 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio.

Key Points: 
  • LONDON, 01 October 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes that its portfolio company LogicBio Therapeutics, Inc. (NASDAQ: LOGC) ("LogicBio"), has announced the pricing of its underwritten public offering in the United States of 7,000,000 shares of common stock, at a public offering price of $6.00 per share, for total gross proceeds of approximately $42.0 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio.
  • In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock, at the public offering price less underwriting discounts and commissions.
  • The offering is expected to close on 5 October 2020, subject to the satisfaction of customary closing conditions.
  • Arix has agreed to invest $3.0 million in the offering and retains a stake of 9.4% in LogicBio.

Travis Perkins: Total Voting Rights

Thursday, October 1, 2020 - 2:09pm

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with DTR5.6.1R, the Company notifies the market of the following:
    As at the date of this announcement, the Company's issued share capital consists of 252,143,923 ordinary shares with a nominal value of 10 pence each ("Ordinary Shares"), with voting rights.
  • The Company does not hold any Ordinary Shares in Treasury.
  • Therefore, the total number of Ordinary Shares with voting rights is 252,143,923.

SThree: Voting Rights and Capital

Thursday, October 1, 2020 - 12:04pm

At the date of this announcement, SThree plc's issued share capital consists of 132,923,225 ordinary shares of 1p each.

Key Points: 
  • At the date of this announcement, SThree plc's issued share capital consists of 132,923,225 ordinary shares of 1p each.
  • Currently there are 49,773 shares held in Treasury, and the total number of voting rights in SThree plc is 132,873,452
    Shareholders may use the above figure of 132,873,452 as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change in their interest in, SThree plc under the FCA's Disclosure and Transparency Rules.

Director/PDMR Shareholding

Thursday, October 1, 2020 - 12:04pm

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Company announces that on 30 September 2020, the following ordinary 10 pence shares of the Company ("Shares") granted in 2011 subject to option under the Company's Long Term Incentive Plan, were exercised and sold in full by Julian Lee, a director of Howden Joinery Limited and a Person Discharging Managerial Responsibility ("PDMR"):

Fuller, Smith & Turner PLC: Total Voting Rights

Thursday, October 1, 2020 - 10:01am

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The following notification is made in accordance with the UK Financial Conduct Authority Disclosure and Transparency Rule 5.6.1.
  • Of this total, 1,274,253 'A' ordinary shares are held in treasury.
  • Therefore, the total number of listed voting rights in Fullers is 32,345,581.